摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-乙酰基-7-羟基-1,2,3,4-四氢异喹啉 | 99365-65-8

中文名称
2-乙酰基-7-羟基-1,2,3,4-四氢异喹啉
中文别名
——
英文名称
2-acetyl-7-hydroxy-1,2,3,4-tetrahydroisoquinoline
英文别名
2-acetyl-1,2,3,4-tetrahydro-isoquinolin-7-ol;2-Acetyl-1,2,3,4-tetrahydro-isochinolin-7-ol;1-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)ethanone;1-(7-hydroxy-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
2-乙酰基-7-羟基-1,2,3,4-四氢异喹啉化学式
CAS
99365-65-8
化学式
C11H13NO2
mdl
——
分子量
191.23
InChiKey
GIRNJPQDXBBBSG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    40.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS<br/>[FR] DERIVES DE 4, 6-DIALKOXY-CINNOLINE SUBSTITUES EN POSITION 4 EN TANT QU'INHIBITEURS DE PHOSPODIESTERASE 10 POUR LE TRAITEMENT DE SYNDROMES PSYCHIATRIQUES OU NEUROLOGIQUES
    申请人:MEMORY PHARM CORP
    公开号:WO2006028957A1
    公开(公告)日:2006-03-16
    The present disclosure relates generally to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by cinnoline compounds of Formulas: (I) and (II); wherein R'-R3 and R15-R18 are as defined herein. Still further, the present invention provides methods for synthesizing compounds with such activity and selectivity, as well as methods of and corresponding pharmaceutical compositions for treating a patient, e.g., mammals, including humans, in need of PDE inhibition. Treatment is preferably for a disease state that involves elevated intracellular PDE10 levels or decreased cAMP and/or cGMP levels, e.g., involving neurological or psychiatric syndromes, especially those states associated with psychoses, most especially schizophrenia or bipolar disorder, obsessive-compulsive disorder, and/or Parkinson’s disease. In particular, such psychoses, obsessive-compulsive disorder, and/or Parkinson’s disease are due at least in part to catabolism of intracellular cAMP and/or cGMP levels by PDE10 enzymes or where such an impaired condition can be improved by increasing cAMP and/or cGMP levels.
    本公开涉及磷酸二酯酶10(PDE10)酶被Formula(I)和(II)的喹啉类化合物抑制;其中R'-R3和R15-R18如本文所定义。此外,本发明提供了合成具有此类活性和选择性的化合物的方法,以及用于治疗需要PDE抑制的患者,例如哺乳动物,包括人类的方法和相应的药物组合物。治疗最好用于涉及细胞内PDE10水平升高或cAMP和/或cGMP水平降低的疾病状态,例如涉及神经系统或精神症候群,尤其是与精神病、强迫症、帕金森病有关的状态。特别是这些精神病、强迫症和/或帕金森病至少部分是由PDE10酶分解细胞内cAMP和/或cGMP水平引起的,或者这种受损状态可以通过增加cAMP和/或cGMP水平来改善。
  • Phosphodiesterase 10 inhibitors
    申请人:Arrington Phillip Mark
    公开号:US20070093515A1
    公开(公告)日:2007-04-26
    Provided are certain quinazolines that are PDE10 inhibitors, pharmaceutical compositions, containing the same and processes for preparing the same. Also provided are methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like, by administering those certain quinazolines.
    提供了某些喹唑啉类化合物作为PDE10抑制剂,以及含有这些化合物的药物组合物和制备这些化合物的方法。同时,还提供了通过给予这些喹唑啉类化合物治疗可由PDE10酶治疗的疾病(如肥胖症、非胰岛素依赖性糖尿病、精神分裂症或躁郁症、强迫症等)的方法。
  • Novel Nucleoside Transport Inhibitors
    申请人:Buolamwini Kwesi John
    公开号:US20070293444A1
    公开(公告)日:2007-12-20
    Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases
    抑制核苷酸转运体的化合物或组合物;以及治疗癌症、心脏病和中风,以及艾滋病和其他传染病的方法。
  • AJAO, J. F.;BIRD, C. W., J. HETEROCYCL. CHEM., 1985, 22, N 2, 329-331
    作者:AJAO, J. F.、BIRD, C. W.
    DOI:——
    日期:——
  • JP2003335760A
    申请人:——
    公开号:JP2003335760A
    公开(公告)日:2003-11-28
查看更多